How FDA’s Breakthrough Therapy Designation Program Changed the Rare Disease Space

Ellen Sigal, PhD, the chair and founder of Friends for Cancer Research, discusses how she helped make the concept of the expedited FDA development program a reality.

[@fabry5877]

aa